Literature DB >> 9637458

Total mesenteric excision in the surgical treatment of rectal cancer: a prospective study.

R B Arenas1, A Fichera, D Mhoon, F Michelassi.   

Abstract

BACKGROUND: Total mesorectal excision has been advocated in conjunction with low anterior or abdominoperineal resection as the optimal surgical treatment for rectal cancer. It involves removal of the entire rectal mesentery as an intact unit and maximizes the likelihood of obtaining a negative circumferential margin.
OBJECTIVES: To prospectively validate the efficacy of total mesorectal excision in obtaining locoregional control, to identify the perioperative factors influencing the selection of either a sphincter sparing or a sphincter ablating procedure, and to identify independent factors that may influence long-term prognosis in rectal cancers. SETTINGS: Tertiary referral center. PATIENTS: Seventy-three consecutive patients with rectal cancer located within 10 cm of the anal verge were treated from 1984 to 1997 by the senior author (F.M.). Sixty-five patients form the basis of our analysis after the exclusion of 7 patients who had their cancer removed transanally and 1 patient who had a permanent diverting stoma as the only procedure.
RESULTS: Twenty-six patients underwent a sphincter ablating procedure; 39 underwent a sphincter sparing procedure. Operative mortality was 1.5%. Follow-up was complete in 64 patients (39+/-30 months; range, 3-126 months). Five-year actuarial survival rates were 88% for the 34 patients with stage I and II adenocarcinoma and 65% for the 22 patients with stage III adenocarcinoma. The local recurrence rate was 6.2% overall, but only 3.1% in the potentially curable group (stages I-III). When only patients who did not receive adjuvant chemoradiation therapy were considered (n=23), local recurrence rate was 8.3% overall and 0% in the potentially curable group. Tumor stage (P=.04) and vascular and/or lymphatic invasion (P=.002) were statistically significant in their association with survival. Circumferential lesions (P<.001), gross invasion of contiguous organs (P<.001) and distance from the anal verge of less than 5 cm (P=.01) were statistically significant in their association with the choice of a sphincter ablating procedure.
CONCLUSIONS: This study confirms the efficacy of total mesorectal excision in minimizing locoregional recurrence rates and confirms the well-established prognostic value of stage and microinvasion. Moreover, it indicates that circumferential lesions, distance from anal verge, and gross invasion of contiguous organs are significant perioperative factors in the selection of the type of surgical procedure.

Entities:  

Mesh:

Year:  1998        PMID: 9637458     DOI: 10.1001/archsurg.133.6.608

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  23 in total

1.  Surgery of rectal cancer: still not a science.

Authors:  Federico Bozzetti
Journal:  Int J Colorectal Dis       Date:  2003-10-03       Impact factor: 2.571

2.  The cluster-randomized Quality Initiative in Rectal Cancer trial: evaluating a quality-improvement strategy in surgery.

Authors:  Marko Simunovic; Angela Coates; Charles H Goldsmith; Lehana Thabane; Dana Reeson; Andrew Smith; Robin S McLeod; Franco DeNardi; Timothy J Whelan; Mark N Levine
Journal:  CMAJ       Date:  2010-08-09       Impact factor: 8.262

Review 3.  Evolving management of colorectal cancer.

Authors:  Jochem van der Voort van Zijp; Harald J Hoekstra; Marc D Basson
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

4.  Simplification of total mesorectal excision with colonic J-pouch anal anastomosis for middle and lower rectal cancer: one surgeon's experience.

Authors:  Masato Kusunoki; Yasuhiro Inoue; Hidenori Yanagi
Journal:  Surg Today       Date:  2008-07-31       Impact factor: 2.549

5.  Changes in treatment of rectal cancer: increased use of low anterior resection.

Authors:  A Mekras; A Michalopoulos; V N Papadopoulos; D Mekras; V Kalles; I Tzeveleki; G Dabakis; S Netta; G Basdanis
Journal:  Tech Coloproctol       Date:  2011-10       Impact factor: 3.781

6.  Laparoscopic versus open surgery for extraperitoneal rectal cancer: a prospective comparative study.

Authors:  M Morino; M E Allaix; G Giraudo; F Corno; C Garrone
Journal:  Surg Endosc       Date:  2005-10-03       Impact factor: 4.584

7.  Patterns of use and outcomes for radiation therapy in the Quality Initiative in Rectal Cancer (QIRC) trial.

Authors:  Valerie Francescutti; Angela Coates; Lehana Thabane; Charles H Goldsmith; Mark N Levine; Marko Simunovic
Journal:  Can J Surg       Date:  2013-12       Impact factor: 2.089

8.  Sphincter-sparing resection for rectal cancer.

Authors:  Kirk A Ludwig
Journal:  Clin Colon Rectal Surg       Date:  2007-08

9.  Comparative evaluation of immune response after laparoscopical and open total mesorectal excisions with anal sphincter preservation in patients with rectal cancer.

Authors:  Jian-Kun Hu; Zong-Guang Zhou; Zhi-Xin Chen; Lan-Lan Wang; Yong-Yang Yu; Jin Liu; Bo Zhang; Li Li; Ye Shu; Jia-Ping Chen
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

10.  Total mesorectal excision for rectal cancer in an unselected population: quality assessment in a low volume center.

Authors:  Floris T J Ferenschild; Imro Dawson; Johannes H W de Wilt; Eelco J R de Graaf; Richard P R Groenendijk; Geert W M Tetteroo
Journal:  Int J Colorectal Dis       Date:  2009-06-02       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.